CR8730A - Compuestos de metil-aril o heteroaril- amida sustituida - Google Patents

Compuestos de metil-aril o heteroaril- amida sustituida

Info

Publication number
CR8730A
CR8730A CR8730A CR8730A CR8730A CR 8730 A CR8730 A CR 8730A CR 8730 A CR8730 A CR 8730A CR 8730 A CR8730 A CR 8730A CR 8730 A CR8730 A CR 8730A
Authority
CR
Costa Rica
Prior art keywords
methyl
heteroaril
amida
aril
substituted compounds
Prior art date
Application number
CR8730A
Other languages
English (en)
Inventor
Koike Hiroki
Matsumoto Yukari
Yamagishi Tatsuya
Okumura Yoshiyuki
Nakao Kazunari
Kon-I Kana
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CR8730A publication Critical patent/CR8730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a nuevos compuestos de metil-aril o heteroaril-amida sustituida. Estos compuestos son utiles como agonistas del receptor de prostaglandinas E2 y por lo tanto son utiles para tratar o aliviar el dolor y la inflamacion y otros trastornos asiociados con la inflamacion.
CR8730A 2004-05-04 2006-11-03 Compuestos de metil-aril o heteroaril- amida sustituida CR8730A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04

Publications (1)

Publication Number Publication Date
CR8730A true CR8730A (es) 2006-11-30

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8730A CR8730A (es) 2004-05-04 2006-11-03 Compuestos de metil-aril o heteroaril- amida sustituida

Country Status (29)

Country Link
US (2) US7534914B2 (es)
EP (1) EP1756042B8 (es)
JP (1) JP4054368B2 (es)
KR (1) KR20070006891A (es)
CN (1) CN1950333A (es)
AP (1) AP2006003785A0 (es)
AR (1) AR048642A1 (es)
AU (1) AU2005238291A1 (es)
BR (1) BRPI0510666A (es)
CA (1) CA2565813C (es)
CR (1) CR8730A (es)
DO (1) DOP2005000071A (es)
EA (1) EA200601847A1 (es)
EC (1) ECSP066968A (es)
ES (1) ES2461265T3 (es)
GT (1) GT200500101A (es)
IL (1) IL178676A0 (es)
MA (1) MA28571B1 (es)
MX (1) MXPA06011555A (es)
NL (1) NL1028947C2 (es)
NO (1) NO20065578L (es)
PA (1) PA8631201A1 (es)
PE (1) PE20060306A1 (es)
SV (1) SV2005002102A (es)
TN (1) TNSN06358A1 (es)
TW (1) TW200536541A (es)
UY (1) UY28877A1 (es)
WO (1) WO2005105732A1 (es)
ZA (1) ZA200608393B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035890A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
US8008062B2 (en) 2005-12-28 2011-08-30 Basf Se Production of (R)- and (S)-4-(1-aminoethyl) benzoic acid methyl ester sulfate by lipase acylation of racemic 4-(1-aminoethyl) benzoic acid methyl ester and sulfuric acid precipitation
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
WO2008017164A1 (en) * 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20110287112A1 (en) 2009-01-30 2011-11-24 Ono Pharmaceutical Co., Ltd. Prostate cancer progression inhibitor and progression inhibition method
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
BR112012020236A2 (pt) 2010-02-22 2016-05-17 Raqualia Pharma Inc uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
RU2565596C2 (ru) 2011-07-04 2015-10-20 Роттафарм Биотек С.Р.Л. Производные циклических аминов в качестве антагонистов рецептора ер4
JP2014525501A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
KR20140059825A (ko) 2011-08-29 2014-05-16 티코나 엘엘씨 고유동성 액정 중합체 조성물
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
WO2013032967A1 (en) 2011-08-29 2013-03-07 Ticona Llc Cast molded parts formed form a liquid crystalline polymer
CN103764623B (zh) 2011-08-29 2016-04-27 提克纳有限责任公司 芳族酰胺化合物
CN103764741B (zh) 2011-08-29 2015-09-23 提克纳有限责任公司 低熔体粘度液晶聚合物的熔融聚合
WO2013032977A1 (en) 2011-08-29 2013-03-07 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
TW201319023A (zh) 2011-08-29 2013-05-16 Ticona Llc 具改良低剪切黏度之熱向性液晶聚合物
US8669341B2 (en) 2011-08-29 2014-03-11 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
KR102239641B1 (ko) * 2013-03-19 2021-04-13 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
US9206300B2 (en) 2013-06-07 2015-12-08 Ticona Llc High strength thermotropic liquid crystalline polymer
BR112015030315B1 (pt) 2013-06-12 2022-10-04 Kaken Pharmaceutical Co., Ltd Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4
CN105793242B (zh) * 2013-12-17 2018-02-16 伊莱利利公司 苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN110612296A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的苯基衍生物
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
MX394108B (es) 2017-05-18 2025-03-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos.
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
IL291783A (en) * 2019-10-02 2022-06-01 Domain Therapeutics ep4 prostaglandin e2 receptor antagonists
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
CN114790176A (zh) * 2021-01-25 2022-07-26 武汉人福创新药物研发中心有限公司 咪唑类化合物及其制备方法和用途
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
SK132899A3 (en) 1997-04-04 2000-09-12 Pfizer Prod Inc NICOTINAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONì (54) COMPRISING THEM
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
AU5283800A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
US6924391B2 (en) * 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
ATE293109T1 (de) 2001-01-31 2005-04-15 Pfizer Prod Inc Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
EP1438973A4 (en) 2001-10-05 2005-07-13 Ono Pharmaceutical Co MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
ECSP066968A (es) 2006-12-29
NL1028947C2 (nl) 2006-04-10
EA200601847A1 (ru) 2007-04-27
CN1950333A (zh) 2007-04-18
US8084476B2 (en) 2011-12-27
PA8631201A1 (es) 2005-11-25
AR048642A1 (es) 2006-05-10
US7534914B2 (en) 2009-05-19
EP1756042A1 (en) 2007-02-28
ES2461265T3 (es) 2014-05-19
NL1028947A1 (nl) 2005-11-07
MA28571B1 (fr) 2007-05-02
AP2006003785A0 (en) 2006-10-31
SV2005002102A (es) 2005-12-13
BRPI0510666A (pt) 2007-12-04
EP1756042B8 (en) 2014-06-04
DOP2005000071A (es) 2005-11-30
EP1756042B1 (en) 2014-02-12
KR20070006891A (ko) 2007-01-11
TNSN06358A1 (fr) 2008-02-22
CA2565813A1 (en) 2005-11-10
ZA200608393B (en) 2008-05-28
AU2005238291A1 (en) 2005-11-10
NO20065578L (no) 2007-01-12
US20090163558A1 (en) 2009-06-25
WO2005105732A1 (en) 2005-11-10
JP4054368B2 (ja) 2008-02-27
CA2565813C (en) 2010-10-26
UY28877A1 (es) 2005-12-30
WO2005105732A8 (en) 2007-04-19
IL178676A0 (en) 2007-02-11
JP2007536366A (ja) 2007-12-13
MXPA06011555A (es) 2006-12-15
TW200536541A (en) 2005-11-16
PE20060306A1 (es) 2006-04-14
GT200500101A (es) 2005-12-12
US20050267170A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY27884A1 (es) Moduladores del receptor de glucocorticoides
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
CO6410303A2 (es) Nicotinamidas sustituidas como moduladores de kcnq2/3
CR11284A (es) Sulfonamidas como moduladores de trpm8
CO6410292A2 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
NI201100052A (es) Derivados de picolinamida como inhibidores de cinasa.
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
SV2011003807A (es) Composiciones y metodos de uso para anticuerpos terapeuticos
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
NI201000090A (es) Agonistas novedosos de los receptores de glucocorticoides.
UY30987A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
CL2012001688A1 (es) Compuestos derivados 2,7 - disustituida - 1 - (4-halo fenil) -1,2,5,6 - tetrahidroisoquinolin - 3(4h) - ona; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades proliferativas.
BR112022023025A2 (pt) Moduladores de htt para tratar doença de huntington
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
ECSP15007358A (es) Pirrol carboxamidas fluorometilo sustituidas
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)